Please assess the completion status of the following clinical trial:

Trial Title: First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 13.0

Eligibility Criteria:
Inclusion Criteria:~* Adult men and women of non-childbearing potential, with total body weight greater than or equal to 50.0 kilogram and body mass index (BMI) between 19.0 kilogram per meter square(kg/m\^2) and 29.9 kg/m\^2.~* Healthy as assessed by the Investigator with no clinically significant abnormality identified on physical examination or laboratory evaluation and no active clinically significant disorder, condition, infection or disease that would pose a risk to participant safety or interfere with the trial evaluation, procedures, or completion.~* Other protocol defined inclusion criteria could apply.~Exclusion Criteria:~* Participants with history or presence of clinically relevant respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological dermatological, connective tissue diseases or disorders.~* Participants with history of relevant drug hypersensitivity, ascertained or presumptive allergy/hypersensitivity to the active drug substance and/or formulation ingredients; history of serious allergic reactions leading to hospitalization or any other allergic reaction in general, which the Investigator considers may affect the safety of the participant and/or outcome of the trial.~* Participants who have any history of malaria.~* Participants who have participated in a previous malaria vaccine trial.~* Participants who have participated in a previous human malaria challenge trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Part A: Placebo (Pooled) (Type: PLACEBO_COMPARATOR): Participants received capsules containing 50 milligram (mg) of placebo matched similar to M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose.
- Part A: Cohort 1 SAD: M5717 50 mg (Type: EXPERIMENTAL): Participants received single ascending dose (SAD) of 50 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
- Part A: Cohort 2 SAD: M5717 100 mg (Type: EXPERIMENTAL): Participants received SAD of 100 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
- Part A: Cohort 3 SAD: M5717 200 mg (Type: EXPERIMENTAL): Participants received SAD of 200 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
- Part A: Cohort 4 SAD: M5717 400 mg (Type: EXPERIMENTAL): Participants received SAD of 400 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
- Part A: Cohort 5 SAD: M5717 600 mg (Type: EXPERIMENTAL): Participants received SAD of 600 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
- Part A: Cohort 6 SAD: M5717 1000 mg (Type: EXPERIMENTAL): Participants received SAD of 1000 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
- Part A: Cohort 7 SAD: M5717 1250 mg (Type: EXPERIMENTAL): Participants in SAD received an oral dose of 1250 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
- Part A: Cohort 8 SAD: M5717 1800 mg (Type: EXPERIMENTAL): Participants in SAD received an oral dose of 1800 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
- Part A: Cohort 9 SAD: M5717 2100 mg (Type: EXPERIMENTAL): Participants in SAD received an oral dose of 2100 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
- Part C: Challenge Cohort 2 M5717 150 mg (Type: EXPERIMENTAL): Participants received single oral dose of 150 mg M5717 (eight days after the administration of intravenous malaria inoculum) on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
- Part C: Challenge Cohort 1 M5717 400 mg (Type: EXPERIMENTAL): Participants received single oral dose of 400 mg M5717 (eight days after the administration of intravenous malaria inoculum) on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
- Part C: Challenge Cohort 3 M5717 800 mg (Type: EXPERIMENTAL): Participants received single oral dose of 800 mg M5717 (eight days after the administration of intravenous malaria inoculum) on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.

Based on this trial design, predict the completion outcome and termination type (if applicable).